INTRODUCTION

Epithelial ovarian cancer (OvCa), a histopathologically, morphologically, and molecularly heterogeneous group of neoplasms.\(^1\) It is the fifth leading cause of cancer deaths among women in the developed world and the most lethal gynecological malignancy.\(^2\) Greater than 75% of ovarian cancer cases go undetected until an advanced stage, which is difficult to treat effectively.\(^3\) Due to the poor prognosis, the identification of potential factors with...
therapeutic potential in OvCa may have important clinical implications.

Epithelial ovarian cancer is highly heterogeneous with different genetic subtypes conferring distinct prognosis. Besides well-established truncal TP53 mutations, HGSOCC is also characterized with the high frequency of CCNE1 amplification and resulting upregulation (~30%). This genotype is termed Cyclin E1-driven HGSOCC. Of OvCa with intact homologous recombination function, amplification of CCNE1, which encodes the cell-cycle regulator cyclin E1, is the best-characterized driver. CCNE1-amplification or gain occurs in 20% of all high-grade OvCa tumors and is associated with primary treatment resistance and reduced overall survival in the entity. A recent study, however, shows that 19q12 amplified and nonamplified subsets of high-grade serous ovarian cancer with the overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes, indicating that Cyclin E1-driven OvCa should be subgrouped by CCNE1 amplification or overexpression.

Cancer immunity plays critical role in combating the disease. Contemporary understanding of the immune checkpoint blockade (ICB) has made a handful of refractory cancers controllable or even curable. Nevertheless, here are currently no approved immune therapies for ovarian cancer. Lack of satisfactory response rate and durable effect are bottlenecks to extend ICB to OvCa. Therefore, elucidating genetic modulation on cancer immunity, especially for driver genes, may have important implications.

In the current study, we focus on the noncanonical gene enrichment and functional annotation in CCNE1-amplified OvCa. With in vitro and in vivo modeling of the genotype, we aim at breaking bottleneck of treatment dilemma of OvCa and our findings may hold promise to precision targeted therapy for OvCa.

2 | MATERIALS AND METHODS

2.1 | In silico analysis

The TCGA database of high-grade serous ovarian cancer was utilized and analyzed using the cBioPortal platform.

2.2 | GSEA

The GESA tool was used to analyze gene enrichment in CCNE1-amplified OvCa cases. GSEA-3.0.jar software was used and gene sets (“c2.cp.kegg.v6.2.symbols.gmt” and “c7.all.v6.2.symbols.gmt[immunologic signatures]”) from the website of Broad Institute and ran it under the support of Java 8.0. We considered cases with CCNE1 amplified (z-score threshold: ±2) as group “CCNE1 altered” and the rest as “CCNE1 unchanged”.

2.3 | TIMER

Correlations between gene expressions and immune infiltrates were studied using the TIMER (Tumor Immune Estimation Resource, https://cistrome.shinyapps.io/timer/) platform.

2.4 | GEPIA

Correlations between the expressions of genes and “Exhausted T cells” gene signature were analyzed using the GEPIA platform (http://gepia.cancer-pku.cn/).

2.5 | Cell lines

Cyclin E1-driven ovarian cancer cell lines (OVCAR-3 and A2780) were selected from the COSMIC database (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) and obtained from the cell bank of Chinese Academy of Science. Both cell lines were cultured in complete RPMI-1640 media supplemented with fetal bovine serum. Transcripts for shRNA construction targeting CCNE1, SRM, and PGC-1α (PPARGC1A) are selected from the The RNAi Consortium (TRC, http://www.broadinstitute.org/rnai/public/). Two transcripts for each gene were selected for testing (CCNE1: TRCN0000045299 and TRCN0000045298; SRM: Clone IDs TRCN0000364085 and TRCN0000001165). Vectors with resistance to puromycin were constructed for knockdown and wild-type paired cell lines via nonlipofectamine Fugene transfection. Medium was replaced with complete medium supplemented with 1:5000 of puromycin and changed every 3 days until all clones were negative for CDK2 or PPARGC1A expression. Similar methods were used to generate control cells.

2.6 | Polyamine detection and quantification

The liquid chromatographic approach was used and chromatographic plate was prepared as per protocol. Standard polyamine solution was prepared using spermine, spermidine, cadecine, and putrescine dissolved in 5% perchloric acid at 10, 1, 0.1, and 0.01 mmol/L, respectively. Cell pellets were processed chilled perchloric acid and were centrifuged for supernatant. The crude extracts underwent sulfonation and extraction followed by chromatography. The spots of the polyamine derivative were scraped off and dissolved in 5 mL of ethyl acetate. The supernatant was subjected to fluorescence spectrophotometry. Relative absorbance was normalized for comparison.

2.7 | mRNA expression and western blotting

Total RNA was extracted with Trizol reagent and was converted to cDNA. Primers for CCNE1, PPARGC1A, and SRM
were designed using the PrimerBank (https://pga.mgh.harvard.edu/primerbank/) and corresponding primers were listed as follows: CCNE1 (forward, AAGGAGCGGGAGACATGA; reverse, ACG GTC ACC TTT GCC TTC C), PPARC1A (forward, TCT GAG TCT GTA TGG AGT GAC AT; reverse, CCA AGT CGT TCA CAT CTA GTT CA) and SRM (forward, GTGGTGCGCTATGCTACTG; reverse, CTCTGGAATTCGCTTCG). The relative expression level of each gene was determined by the real-time quantitative PCR using SYBR Premix Ex Taq II (Takara). For western blotting, a standard protocol was followed. Total protein was first extracted and concentration was then determined. Proteins were then separated by SDS-PAGE on a 10% gel and subsequently transferred to a polyvinylidene difluoride membrane. Nonspecific antigens were blocked using nonfat milk and the corresponding primary antibodies were applied according to the manufacturer's recommended protocol and concentration as follows: anti-PD-1 (Abcam, 1:100), anti-PD-L1 (Sigma-Aldrich, 1:100), anti-PD-L2 (R&D, 1:100), anti-SRM (ThermoFisher, 1:500), anti-SMS (ThermoFisher, 1:200), anti-ODC1 (Sigma-Aldrich, 1:1000), anti-MYC (ThermoFisher, 1:200), anti-PGC-1α (Santa Cruz Biotechnology, 1:100), anti-Cyclin E1 (ThermoFisher, 1:1000) and β-catenin (Santa Cruz Biotechnology, 1:200). After corresponding secondary antibodies were applied, protein bands were then detected using chemiluminescence and autoradiography for densitometry detection.

2.8 | Transwell assays

Transwell assay was used to study cell migration and invasion. Briefly, cells were resuspended at the density of 1 × 10⁶/mL in 300 μL of serum-free medium and seeded in the upper chamber of Transwell without any coating for migration and with Matrigel coating for invasion. The lower chambers were then filled with 500 μl of complete medium and cells migrated through the membrane were stained with crystal violet and counted.

2.9 | Statistical analysis

Comparisons between groups were analyzed with the two-tailed Student's *t* test. The *P* value of .05 was accepted as statistically significant.

3 | RESULTS

3.1 | Polyamine metabolism is upregulated in Cyclin E1-driven OvCa

Using robust sequencing data of tissue samples from TCGA database, we found that polyamine metabolism was significantly enriched in Cyclin E1-driven OvCa (Figure 1A). We then studied the correlation of expressions between CCNE1 and essential genes involved in polyamine metabolism and found that the expressions of SMS, SRM, and ODC1 were positively correlated with that of CCNE1, respectively (Figure 1B). We previously reported that PGC-1α was downstream of Cyclin E1 and PGC-1α was reported to regulate polyamine synthesis in prostate cancer. We therefore queried the expressions of PPARC1A against polyamine genes and found that the expressions of SMS, SRM, and ODC1 were positively correlated with that of CCNE1, respectively (Figure 1C). As polyamine was reported to mediate microenvironment and cancer immunity, we queried the expressions of CCNE1 and polyamine genes again immune infiltrates and found that the CCNE1 expression was significantly correlated with macrophage and neutrophil infiltration (Figure 1D). For polyamine genes, SMS expression was not correlated with immune infiltrates, whereas expressions of both ODC1 and SMS were significantly correlated with the decreased infiltration of B cell, CD8⁺ cells, macrophage, neutrophil and dendritic cells, respectively (Figure 1D). Here we show polyamine pathway was enriched in Cyclin E1-driven OvCa we next tried to pinpoint the polyamine gene downstream of CCNE1.

3.2 | PGC-1α suppresses polyamine synthesis in Cyclin E1-driven OvCa

To validate the effect of PGC-1α on polyamine synthesis, we performed a series of Transwell assays to profile cancer invasiveness. We first found PGC-1α silencing significantly decreased invasion and migration in both OvCa cell lines (Figure 2A,B). Supplement of PGC-1α with adenovirus restored invasion in both cells (Figure 2C). Both spermidine and spermine levels were significantly increased when PGC-1α was silenced in OVCAR3 cells (Figure 2D). Targeting SRM significantly decreased spermine level in OVCAR3 cells, which was rescued when PGC-1α was silenced (Figure 2E). PGC-1α silencing significantly increased spermine level which was further increased in the presence of spermidine (Figure 2E).

3.3 | Targeting polyamine metabolism suppresses Cyclin E1-driven OvCa

As MYC was reported to mediate polyamine metabolism and MYC was frequently amplified in OVCA and overlapped in part with CCNE1-amplified cases, we first queried MYC-amplified case in TCGA cohort and found that polyamine metabolism was not enriched (Figure 3A). Silencing of PGC-1α resulted in increased SRM in both OvCa cells yet showed minimal effect on ODC1 or SMS (Figure 3B). Silencing of CCNE1 induced increased SRM level and silencing of PGC-1α blocked the effect (Figure 3C). CCNE1 silencing significantly decreased the invasion and migration of OVCAR3 cells, whereas PGC-1α silencing abolished the effect (Figure 3D). Similarly, CDK2 inhibitor Dinaciclib
FIGURE 1 Polyamine metabolism is upregulated in Cyclin E1-driven OvCa. Reproduced from TGCA OvCa database using (A) GSEA showing enrichment of polyamine metabolic genes; (B) GEPIA showing correlations between expressions of CCNE1 and polyamine genes; (C) GEPIA showing correlations between expressions of PGC-1α and polyamine genes; and (D) TIMER showing correlations between expressions of genes
significantly decreased the invasion and migration of OVCAR3 cells, whereas PGC-1α silencing abolished the effect (Figure 3E). Targeting SRM significantly inhibited the invasion of both OvCa cell lines which could be restored by spermidine supplement or PGC-1α silencing (Figure 3F).

3.4 Targeting CDK2 induces PD-L1 upregulation in tumor cells

As polyamine was reported to mediate cancer immunity, we here studied its impact on immune checkpoint molecules. Expression of PD-1 was predominantly in tumor cells showing no correlation with CD4+ or CD8+ infiltrates (Figure 4A). Expressions of PD-L1 and PD-L2 were predominantly in tumor-infiltrating lymphocytes and showed significant negative correlations with CD4+ or CD8+ infiltrates, respectively (Figure 4B,C). CCNE1 but not CDK2 expression showed significant positive correlation with the expressions of PD-1, PD-L1, and PD-L2, respectively (Figure 4D). Expressions of CCNE1 and CDK2 were positively correlated with the gene signature of exhausted T cells (Figure 4E). Application of Dinaciclib in OvCa cells showed no notable effect of PD-1 yet substantially induced the increased levels of PD-L1 and PD-L2 (Figure 4F).

4 DISCUSSION

In the current study, we have shown that polyamine metabolism is upregulated in Cyclin E1-driven OvCa. PGC-1α suppresses polyamine synthesis in Cyclin E1-driven OvCa. Targeting polyamine metabolism suppresses Cyclin E1-driven OvCa. Targeting CDK2 induces PD-L1 upregulation in tumor cells. Modulation of polyamine metabolism by CCNE1 has not been reported before and has previously been mechanistically unrelated. Our findings further direct Cyclin E1 signaling to tumor microenvironment and notably, the immune checkpoint signaling. Cyclin D-CDK4 kinase has been reported to destabilize PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Together with our findings, it is highly possible that PD-L1 protein stability can be regulated by a cell cycle kinase, revealing the potential for using combination treatment with CDK2 inhibitors and PD-1-PD-L1 ICB to enhance therapeutic efficacy for OvCa.
Polyamine plays a role in cancer. The polyamines putrescine, spermidine, and spermine are polycationic amines and are present in mammalian cells in millimolar concentrations. The direct interplay between oncogenes and polyamine metabolism was first apparent with the demonstration that ODC was a transcriptional target of the MYC oncogene. RAS activation has been associated with increased polyamine transport by colon tumor cells. It has also been demonstrated, in a series of human hepatocellular carcinomas and colon carcinoma cell models, that polyamine depletion through the overexpression of SSAT is a result of decreased AKT signaling and reduced nuclear β-catenin leading to decreased cell growth, migration, and invasion. The PTEN–PI3K–mTOR complex 1 (mTORC1) pathway has been shown to be linked with polyamine metabolism in prostate cancer through the upregulation of AMD1. A noncanonical Hedgehog signaling pathway has recently been implicated in the upregulation of polyamine biosynthesis in the precursor lesion to medulloblastoma.

Polyamine has also been associated with cancer immunity. Polyamine-blocking therapy is reported to promote the antitumor immune response, resulting in even greater antitumour effects than would be expected from polyamine depletion in tumor cells alone. In immune-competent mouse models of lymphoma, melanoma, and colon cancer, treatment with the combination of DFMO plus AMXT 1501 led to a decrease in tumor-infiltrating myeloid suppressor cells and an increase in CD3+ T cells, resulting in inhibition of tumor growth. ODC activity and polyamines favor the tumor-tolerant M2-like phenotype while reducing the antitumor M1-like phenotype. These findings are consistent with earlier work implicating ODC in the regulation of M1 macrophages.

In the current study, we have also found that increased polyamine gene expression is associated with less immune infiltrates. We have further pursued correlation between...
FIGURE 4  Targeting CDK2 induces PD-L1 upregulation in tumor cells. Reproduced from TGCA OvCa database using TIMER showing correlations between tumor purity and expressions of (A) PD-1; (B) PD-L1; and (C) PD-L2; and showing expressions between genes; Reproduction using GEPIA showing expressions of CCNE1 and CDK2 in association with exhausted T-cell signature genes; (D) western blotting showing effect of Dinaciclib on immune checkpoint molecules in both OvCa cells; (E) correlations of expression of genes within "Exhausted T cell signature" from GEPIA platform with expressions of CCNE1 and CDK2, respectively; (F) western blotting showing effect of Dinaciclib on levels of immune checkpoint molecules.
polyamine and immune checkpoint molecules. Based on our findings, we speculate that Cyclin E1-driven, in particular CCNE1-amplified OvCa exert immune exclusion mainly via expression PD-L1/L2 in TILs. Positive correlation between expressions of CCNE1 and PD-L1/L2 revealed in TCGA dataset may result from response to TIL in the microenvironment. This corresponds to the in vitro observation that when CDK2 inhibitor is applied, PD-L1/L2 in tumor is upregulated as a mechanism of resistance to would be decreased negative immune modulation. Although those speculations warrant validation, our findings hold promise for optimizing current ICB application in OvCa. Both polyamine deprivation and CDK2 inhibition is theoretically expected to sensitize cells to ICB.

ACKNOWLEDGMENTS
This study was supported in part by the National Natural Science Foundation of China (Grant No. 81602288) and National Key R&D Program of China (Grant No. 2016YFC1303100).

CONFLICT OF INTEREST
None.

ORCID
Congjian Xu https://orcid.org/0000-0001-6240-827X

REFERENCES
1. Vaughan S, Coward JJ, Bast RC, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11:719-725.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34.
3. Emmins E, Mullany S, Chang Z, Landen CN, Linder S, Bazzaro M. Targeting mitochondria for treatment of chemoresistant ovarian cancer. Int J Mol Sci. 2019;20:229.
4. N. Cancer Genome Atlas Research. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-615.
5. Etemadmoghadam D, deFazio A, Beroukhim R, et al. Integrated genome-wide DNA copy number and expression analysis identifies mechanism of primary chemoresistance in ovarian carcinomas. Clin Cancer Res. 2009;15:1417-1427.
6. Au-Yeung G, Lang F, Azar WJ, et al. Selective targeting of Cyclin E1-amplified high-grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition. Clin Cancer Res. 2017;23:1862-1874.
7. Aziz D, Etemadmoghadam D, Caldon CE, et al. 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes. Gynecol Oncol. 2018;151:327-336.
8. Odusi K. Immunotherapy in ovarian cancer. Ann Oncol. 2017;28:vii1-viii7.
9. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.
10. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545-15550.
11. Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108-e110.
12. Li B, Severson E, Pignon JC, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17:174.
13. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98-W102.
14. Kaminski L, Torrino S, Dufies M, et al. PGC-1α inhibits polyamine synthesis to suppress prostate cancer aggressiveness. Can Res. 2019;79:3268-3280.
15. Guo T, Li B, Gu C, Chen X, Han M, Liu X, Xu C. GCN-5/PGC-1α signaling is activated and associated with metabolism in cyclin E1-driven ovarian cancer. Aging. 2019;11:4890-4899.
16. Flynn A, Hogarty M. Myc, oncogenic protein translation, and the role of polyamines. Med Sci. 2018;6:41.
17. Zhang J, Bu X, Wang H, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance. Nature. 2017;553:91-95.
18. Pegg AE, Casero RA Jr. Current status of the polyamine research field. Methods Mol Biol. 2011;720:3-35.
19. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of e-Myc. Proc Natl Acad Sci. 1993;90:7804-7808.
20. Roy U, Rial NS, Kachel KL, Gerner EW. Activated K-RAS increases polyamine uptake in human colon cancer cells through modulation of caveolar endocytosis. Mol Carcinog. 2008;47:538-553.
21. Wang C, Ruan P, Zhao Y, et al. Spermidine/spermine N1-acetyltransferase regulates cell growth and metastasis via AKT/p-catenin signaling pathways in hepatocellular and colorectal carcinoma cells. Oncotarget. 2017;8:1092-1109.
22. Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, et al. mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature. 2017;547:109-113.
23. D’Amico D, Antonucci L, Di Magno L, et al. Non-canonical Hedgehog/AMPK-mediated control of polyamine metabolism supports neural and medulloblastoma cell growth. Dev Cell. 2015;35:21-35.
24. Hayes CS, Shicora AC, Keough MP, Snook AE, Burns MR, Gilmour SK. Polyamine-blocking therapy reverses immunosuppression in the tumor microenvironment. Cancer Immunol Res. 2013;2:274-285.
25. Alexander ET, Minton A, Peters MC, Phanstiel O, Gilmour SK. A novel polyamine blockade therapy activates an anti-tumor immune response. Oncotarget. 2017;8:84140-84152.